Which has preferable valuation and earnings, FTH or INAB?

IN8bio is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A IN8bio N/A N/A -$19.44M -$1.62 N/A

Is FTH or INAB more profitable?

IN8bio's return on equity of -91.18% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -1,012.17% -175.69% IN8bio N/A -91.18% -76.93%

Does the media prefer FTH or INAB?

In the previous week, IN8bio had 5 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 13 mentions for IN8bio and 8 mentions for Sensei Biotherapeutics. IN8bio's average media sentiment score of 0.78 beat Sensei Biotherapeutics' score of 0.42 indicating that IN8bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend APLM or INAB?

IN8bio has a consensus target price of $4.00, indicating a potential upside of 263.64%. Given IN8bio's stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, APLM or INAB?

Apollomics has higher revenue and earnings than IN8bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.83 -$10.94M N/A N/A IN8bio N/A N/A -$19.44M -$1.62 N/A

Is APLM or INAB more profitable?

Apollomics' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A IN8bio N/A -91.18% -76.93%

Does the media prefer APLM or INAB?

In the previous week, IN8bio had 10 more articles in the media than Apollomics. MarketBeat recorded 13 mentions for IN8bio and 3 mentions for Apollomics. IN8bio's average media sentiment score of 0.78 beat Apollomics' score of 0.62 indicating that IN8bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INAB or DYAI?

In the previous week, IN8bio had 1 more articles in the media than Dyadic International. MarketBeat recorded 13 mentions for IN8bio and 12 mentions for Dyadic International. IN8bio's average media sentiment score of 0.78 beat Dyadic International's score of 0.10 indicating that IN8bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, RADX or INAB?

IN8bio has lower revenue, but higher earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $3.63M 9.23 -$24.83M N/A N/A IN8bio N/A N/A -$19.44M -$1.62 N/A

Is RADX or INAB more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A IN8bio N/A -91.18% -76.93%

Do analysts rate LTRN or INAB?

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 263.64%. Given IN8bio's stronger consensus rating and higher probable upside, analysts clearly believe IN8bio is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, LTRN or INAB?

Lantern Pharma is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.45 N/A IN8bio N/A N/A -$19.44M -$1.62 N/A

Is LTRN or INAB more profitable?

IN8bio's return on equity of -91.18% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -198.34% -129.08% IN8bio N/A -91.18% -76.93%

Does the media prefer LTRN or INAB?

In the previous week, IN8bio had 8 more articles in the media than Lantern Pharma. MarketBeat recorded 13 mentions for IN8bio and 5 mentions for Lantern Pharma. IN8bio's average media sentiment score of 0.78 beat Lantern Pharma's score of -0.29 indicating that IN8bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IN8bio (INAB) Competitors

$1.10 -0.08 (-6.78%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.11 +0.01 (+0.91%)

As of 08/14/2026 07:34 PM Eastern

Compare

INAB vs. FTH, APLM, DYAI, RADX, and LTRN

Should you buy IN8bio stock or one of its competitors? IN8bio's main competitors and comparable companies include Sensei Biotherapeutics (FTH), Apollomics (APLM), Dyadic International (DYAI), Radiopharm Theranostics (RADX), and Lantern Pharma (LTRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IN8bio compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

IN8bio's return on equity of -91.18% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
IN8bio	N/A	-91.18%	-76.93%

Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market. Comparatively, IN8bio has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

IN8bio is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

Sensei Biotherapeutics presently has a consensus price target of $54.90, indicating a potential upside of 69.76%. IN8bio has a consensus price target of $4.00, indicating a potential upside of 263.64%. Given IN8bio's higher possible upside, analysts plainly believe IN8bio is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 14.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, IN8bio had 5 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 13 mentions for IN8bio and 8 mentions for Sensei Biotherapeutics. IN8bio's average media sentiment score of 0.78 beat Sensei Biotherapeutics' score of 0.42 indicating that IN8bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IN8bio beats Sensei Biotherapeutics on 10 of the 14 factors compared between the two stocks.

How does IN8bio compare to Apollomics?

Apollomics (NASDAQ:APLM) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Apollomics has higher revenue and earnings than IN8bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.83	-$10.94M	N/A	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

IN8bio has a consensus target price of $4.00, indicating a potential upside of 263.64%. Given IN8bio's stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Apollomics' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
IN8bio	N/A	-91.18%	-76.93%

Apollomics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

In the previous week, IN8bio had 10 more articles in the media than Apollomics. MarketBeat recorded 13 mentions for IN8bio and 3 mentions for Apollomics. IN8bio's average media sentiment score of 0.78 beat Apollomics' score of 0.62 indicating that IN8bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IN8bio beats Apollomics on 7 of the 12 factors compared between the two stocks.

How does IN8bio compare to Dyadic International?

IN8bio (NASDAQ:INAB) and Dyadic International (NASDAQ:DYAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

In the previous week, IN8bio had 1 more articles in the media than Dyadic International. MarketBeat recorded 13 mentions for IN8bio and 12 mentions for Dyadic International. IN8bio's average media sentiment score of 0.78 beat Dyadic International's score of 0.10 indicating that IN8bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IN8bio has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Dyadic International has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

IN8bio has a net margin of 0.00% compared to Dyadic International's net margin of -201.43%. IN8bio's return on equity of -91.18% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Dyadic International	-201.43%	-2,920.31%	-84.77%

92.1% of IN8bio shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 14.5% of IN8bio shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

IN8bio currently has a consensus price target of $4.00, indicating a potential upside of 263.64%. Dyadic International has a consensus price target of $3.00, indicating a potential upside of 287.05%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Dyadic International is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dyadic International has higher revenue and earnings than IN8bio. Dyadic International is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Dyadic International	$3.09M	9.14	-$7.36M	-$0.23	N/A

Summary

Dyadic International beats IN8bio on 8 of the 15 factors compared between the two stocks.

How does IN8bio compare to Radiopharm Theranostics?

Radiopharm Theranostics (NASDAQ:RADX) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

92.1% of IN8bio shares are owned by institutional investors. 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, IN8bio had 12 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 13 mentions for IN8bio and 1 mentions for Radiopharm Theranostics. Radiopharm Theranostics' average media sentiment score of 1.87 beat IN8bio's score of 0.78 indicating that Radiopharm Theranostics is being referred to more favorably in the media.

Company	Overall Sentiment
Radiopharm Theranostics	Very Positive
IN8bio	Positive

Radiopharm Theranostics has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Radiopharm Theranostics currently has a consensus target price of $11.00, suggesting a potential upside of 329.69%. IN8bio has a consensus target price of $4.00, suggesting a potential upside of 263.64%. Given Radiopharm Theranostics' stronger consensus rating and higher possible upside, analysts clearly believe Radiopharm Theranostics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Radiopharm Theranostics' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
IN8bio	N/A	-91.18%	-76.93%

IN8bio has lower revenue, but higher earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$3.63M	9.23	-$24.83M	N/A	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

Summary

Radiopharm Theranostics beats IN8bio on 8 of the 12 factors compared between the two stocks.

How does IN8bio compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and IN8bio (NASDAQ:INAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 263.64%. Given IN8bio's stronger consensus rating and higher probable upside, analysts clearly believe IN8bio is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, IN8bio had 8 more articles in the media than Lantern Pharma. MarketBeat recorded 13 mentions for IN8bio and 5 mentions for Lantern Pharma. IN8bio's average media sentiment score of 0.78 beat Lantern Pharma's score of -0.29 indicating that IN8bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 92.1% of IN8bio shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 14.5% of IN8bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantern Pharma has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

IN8bio's return on equity of -91.18% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-198.34%	-129.08%
IN8bio	N/A	-91.18%	-76.93%

Lantern Pharma is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.45	N/A
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A

Summary

IN8bio beats Lantern Pharma on 10 of the 13 factors compared between the two stocks.

Get IN8bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INAB vs. The Competition

Export

Metric	IN8bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.63M	$3.72B	$7.03B	$13.06B
Dividend Yield	N/A	3.69%	2.57%	10.44%
P/E Ratio	-0.68	10.67	268.81	25.28
Price / Sales	N/A	1,232.78	574.46	75.26
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	0.59	16.78	12.91	6.24
Net Income	-$19.44M	-$13.32M	$3.45B	$347.60M
7 Day Performance	12.41%	1.77%	1.11%	1.06%
1 Month Performance	-23.61%	1.16%	1.33%	0.81%
1 Year Performance	-53.59%	54.22%	62.44%	20.90%

IN8bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INAB IN8bio	2.9783 of 5 stars	$1.10 -6.8%	$4.00 +263.6%	-54.2%	$11.63M	N/A	N/A	20	News Coverage Analyst Revision
FTH Sensei Biotherapeutics	4.5496 of 5 stars	$30.33 +6.1%	$54.90 +81.0%	N/A	$40.46M	N/A	N/A	40	News Coverage Analyst Forecast Gap Up
APLM Apollomics	1.3104 of 5 stars	$18.03 +1.0%	N/A	+281.0%	$39.66M	$8.50M	N/A	45	News Coverage Gap Up
DYAI Dyadic International	3.2074 of 5 stars	$1.02 +2.9%	$3.00 +193.0%	-3.1%	$37.17M	$3.09M	N/A	7	News Coverage Earnings Report Analyst Upgrade Short Interest Decrease
RADX Radiopharm Theranostics	3.7943 of 5 stars	$2.80 flat	$11.00 +292.9%	-48.9%	$36.68M	$2.35M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INAB) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IN8bio (INAB) Competitors

INAB vs. FTH, APLM, DYAI, RADX, and LTRN

How does IN8bio compare to Sensei Biotherapeutics?

Summary

How does IN8bio compare to Apollomics?

Summary

How does IN8bio compare to Dyadic International?

Summary

How does IN8bio compare to Radiopharm Theranostics?

Summary

How does IN8bio compare to Lantern Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IN8bio (INAB) Competitors

INAB vs. FTH, APLM, DYAI, RADX, and LTRN

How does IN8bio compare to Sensei Biotherapeutics?

Is FTH or INAB more profitable?

Which has more volatility and risk, FTH or INAB?

Which has preferable valuation and earnings, FTH or INAB?

Do analysts recommend FTH or INAB?

Do institutionals and insiders believe in FTH or INAB?

Does the media prefer FTH or INAB?

Summary

How does IN8bio compare to Apollomics?

Do institutionals & insiders believe in APLM or INAB?

Which has better earnings & valuation, APLM or INAB?

Do analysts recommend APLM or INAB?

Is APLM or INAB more profitable?

Which has more volatility & risk, APLM or INAB?

Does the media prefer APLM or INAB?

Summary

How does IN8bio compare to Dyadic International?

Does the media favor INAB or DYAI?

Which has more risk & volatility, INAB or DYAI?

Is INAB or DYAI more profitable?

Do insiders & institutionals have more ownership in INAB or DYAI?

Do analysts rate INAB or DYAI?

Which has preferable earnings & valuation, INAB or DYAI?

Summary

How does IN8bio compare to Radiopharm Theranostics?

Do institutionals and insiders have more ownership in RADX or INAB?

Does the media prefer RADX or INAB?

Which has more volatility & risk, RADX or INAB?

Do analysts rate RADX or INAB?

Is RADX or INAB more profitable?

Which has better earnings and valuation, RADX or INAB?

Summary

How does IN8bio compare to Lantern Pharma?

Do analysts rate LTRN or INAB?

Does the media prefer LTRN or INAB?

Do institutionals & insiders have more ownership in LTRN or INAB?

Which has more risk and volatility, LTRN or INAB?

Is LTRN or INAB more profitable?

Which has higher valuation and earnings, LTRN or INAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INAB vs. The Competition

IN8bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools